Clinical

Dataset Information

Zinc Supplement in Regorafenib Treated mCRC Patient


ABSTRACT: Phase II randomized trial to investigate whether supplementation of zinc decreases the incidence of HFSR that occurs after treatment of tyrosine kinase inhibitor, regorafenib.

DISEASE(S): Colorectal Neoplasms,Colorectal Cancer Metastatic

PROVIDER: 2301575 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR